Working… Menu

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02591862
Recruitment Status : Completed
First Posted : October 30, 2015
Last Update Posted : June 4, 2018
Radboud University
Information provided by (Responsible Party):
AKARI Therapeutics

Brief Summary:
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Haemoglobinuria (PNH) Drug: Coversin Phase 2

Detailed Description:
Coversin, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5 convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in patients with PNH and proven resistance to eculizumab due to C5 polymorphisms. Patients will be treated with Coversin by daily subcutaneous injection for 6 months in order to determine the safety and efficacy of the drug in these circumstances. If satisfactory control of the PNH is achieved, and at the discretion of the Principal Investigator (PI), patients will have the option of remaining on Coversin and being entered into the long term follow-up study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Actual Study Start Date : February 2016
Actual Primary Completion Date : February 2018
Actual Study Completion Date : March 20, 2018

Arm Intervention/treatment

This is an open label, non-comparator study.

Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given.

Drug: Coversin
Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
Other Name: rVA576

Primary Outcome Measures :
  1. Measurement of Serum Lactic Dehydrogenase (LDH) from Day 0 (pre-dose) to Day 28 (AUC) compared with 28 days pre-treatment [ Time Frame: Day 0 to Day 28 ]
    LDH is an indicator of disease progression in patients with PNH and is expected to fall to within 2x upper limit of normal (ULN) within 28 days in successfully treated patients. Serum LDH less than 100% above Upper Limit Of Normal Total (ULNt) 28 days

Secondary Outcome Measures :
  1. Measurement of Haemoglobin (Hb) [ Time Frame: Day 28 and Day 180 ]
    Measuring change in mean Hb from Day 28 and Day 180 (absolute and change from baseline)

  2. Measurement of Haptoglobin (Hp) [ Time Frame: Day 28 and Day 180 ]
    Measuring change in mean Hp from Day 28 - Day 180 (absolute and change from baseline)

  3. Measurement of Change in LDH [ Time Frame: Day 0 (pre-dose) at monthly intervals up to 1 year ]

    Measuring the change in LDH from Day 0 (pre-dose) and at 24 hrs (pre-dose) 48 hrs (pre-dose) Day 2 Day 5 Day 7,14 and 21 Day 28, 35, 42, 49 Day 60 (weeks 8, 10 and 12) Day 90 (weeks 14, 16, 18, 20 and month 5) Day 180 (months 6, 7, 8, 9, 10 and 11)

    1 year (month 12, and every 3 months) End of study

  4. Change in proportion of PNH [ Time Frame: Day 0 - Day 90 ]
    Measuring the change in proportion of PNH Type III red cells from Day 0 - Day 90

  5. Change in Functional Assessment of Chronic Illness Therapy (FACIT) Score [ Time Frame: Day 0 - Day 180 ]

    Measuring the change in FACIT score from Day 0 - to Day 180. This validation instrument will be used to measure:

    Patient well-being Physical well-being Social/Family well-being Functional well-being

  6. Change in Quality Of Life Questionnaire (QOQ) Score [ Time Frame: Day 0 - Day 180 ]
    Measuring the change in patients quality of life using the European Organization for Research and Treatment of Cancer (EORTC) QOQ C30 instrument. This will assess the quality of of life of patients on this trial.

  7. Number and type of adverse events (AE) [ Time Frame: 6 months ]
    The number and type of reported AEs will be recorded as well as the opinion of the Principle Investigator (PI) as to their possible relationship to the study drug

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with known Paroxysmal Nocturnal Haemoglobinuria (PNH)
  • LDH >=1.5 Upper Limit of Normal (ULN)
  • Resistance to Eculizumab proven by both a recognised C5 polymorphism on genetic screening and complement inhibition on CH50 ELISA of <100% at concentrations of Eculizumab in excess of 5mug/mL
  • Willing to self-inject Coversin daily or to receive daily subcutaneous injections by a home nurse or in a doctor's office or hospital clinic
  • Males or females taking adequate contraceptive precautions if of childbearing potential, 18 - 80 years of age
  • Body weight ≥50kg and ≤ 100kg
  • The patient has provided written informed consent.
  • Willing to avoid prohibited medications for duration of study
  • Must agree to take appropriate prophylactic precautions against Neisseria infection.
  • Must be counselled regarding the possible reproductive risks of using Coversin and be advised to use an adequate method of contraception pending further data on reproductive toxicology.

Exclusion Criteria:

  • Body weight <50kg or>100kg
  • Pregnancy (females)
  • Failure to satisfy the PI of fitness to participate for any other reason
  • Known allergy to ticks or severe reaction to arthropod venom (e.g., bee or wasp venom)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02591862

Layout table for location information
Dr Saskia Langemeijer
Nijmegen, Netherlands, 6525 GA
Sponsors and Collaborators
AKARI Therapeutics
Radboud University
Layout table for investigator information
Principal Investigator: Petra Dr Muus Radboud University
Study Director: Saskia Dr Langemeijer Radboud University
Layout table for additonal information
Responsible Party: AKARI Therapeutics Identifier: NCT02591862    
Other Study ID Numbers: AK578
First Posted: October 30, 2015    Key Record Dates
Last Update Posted: June 4, 2018
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases